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Chronic myeloid leukaemia (CML) is a myeloproliferative disease
originating in a haematopoietic stem cell and is strongly associated
with a cytogenetic abnormality known as the Philadelphia chro-
mosome (Ph) (Nowell and Hungerford, 1960), which is the result
of a reciprocal recombination between chromosomes 9 and 22. As
a consequence the bcr and the abl proto-oncogenes are fused
(Shtivelman et al, 1985). The protein product (p210) of the bcr–abl
oncogene has an elevated protein tyrosine kinase (TK) activity and
has been implicated in the leukaemogenesis (Gishizky and Witte,
1992). Research trying to modulate CML growth has been
focussed mainly on the modulation of the TK function of p210
(Workman, 1992). More specifically, TK inhibitors such as
herbimycin A are being investigated (Fukazawa et al, 1991;
Pendergast et al, 1991; Druker et al, 1996). However, only a few
papers have focussed on the relevance of protein kinase C (PKC)
activity in CML. PKC belongs to a large family of serine/threonine
kinases (reviewed in Wilkinson and Hallam, 1994). Although
p210 itself has no PKC activity the protein can be phosphorylated
on serine and threonine residues by PKC enzymes (Pendergast et
al, 1987). Furthermore p210 transforming potential is in part
dependent on the MAP-kinase pathway which itself is modulated
by PKC enzymes (Sawyers et al, 1995).
Bryostatin belongs to the family of macrocyclic lactones isolated
from the marine bryozoan Bugula Neritina and is a potent activator
of PKC (Berkow and Kraft, 1985; Pettit et al, 1986; Wender et al,
1988; Kraft, 1993). After binding of bryostatin, PKC translocates to
the plasma membrane and starts phosphorylating target proteins on
serine and threonine residues (Wilkinson and Hallam, 1994) thereby
altering protein activity and influencing signal transduction events
(reviewed in Dekker and Parker, 1994). Bryostatin has been demon-
strated to possess both in vivo and in vitro anti-leukaemic potential
(Jones et al, 1990; Grant et al, 1991; reviewed in Steube and Drexler,
1993). Our group has shown that in acute myeloid leukaemia bryo-
statin can reduce leukaemic outgrowth depending on concentration
and time of exposure whereas it can stimulate normal outgrowth (van
der Hem et al, 1995, 1996). Differential effects found on normal and
malignant haematopoiesis (van der Hem et al, 1995) might be
explained by bryostatin-induced secretion of cytokines in accessory
cells such as monocytes (Lilly et al, 1990; Steube and Drexler, 1995;
van der Hem et al, submitted for publication) and stromal cells in
long-term bone marrow cultures (Lilly et al, 1996). The release of
GM–CSF, IL-3 and other related cytokines have been suggested to
stimulate non-leukaemic growth whereas the induction of TNF-a
might suppress leukaemic growth (Steube and Drexler, 1995).
In samples derived from CML patients it has been demonstrated
that bryostatin-1 induces macrophage differentiation and suppresses
colony growth in vitro (Lilly et al, 1990). Bryostatin-1 has also been
shown to induce cell cycle arrest correlating with dephosphorylation
of CDK2 and upregulation of P21 as demonstrated with the U937
cell line and CML-derived cells (Asiedu et al, 1995).
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Summary Bryostatin-1 belongs to the family of macrocyclic lactones isolated from the marine bryozoan Bugula neritina and is a potent
activator of protein kinase C (PKC). Bryostatin has been demonstrated to possess both in vivo and in vitro anti-leukaemic potential. In
samples derived from chronic myeloid leukaemia (CML) patients, it has been demonstrated that bryostatin-1 induces a macrophage
differentiation, suppresses colony growth in vitro and promotes cytokine secretion from accessory cells. We investigated the effect of
bryostatin-1 treatment on colony-forming unit–granulocyte macrophage (CFU–GM) capacity in the presence of accessory cells, using
mononuclear cells, as well as in the absence of accessory cells using purified CD34-positive cells. Cells were obtained from 14 CML patients
as well as from nine controls. Moreover, CD34-positive cells derived from CML samples and controls were analysed for stem cell frequency
and ability using the long-term culture initiating cell (LTCIC) assay at limiting dilution. Individual colonies derived from both the CFU–GM and
LTCIC assays were analysed for the presence of the bcr–abl gene with fluorescence in situ hybridization (FISH) to evaluate inhibition of
malignant colony growth.
The results show that at the CFU–GM level bryostatin-1 treatment resulted in only a 1.4-fold higher reduction of CML colony growth as
compared to the control samples, both in the presence and in the absence of accessory cells. However, at the LTCIC level a sixfold higher
reduction of CML growth was observed as compared to the control samples. Analysis of the LTCICs at limiting dilution indicates that this
purging effect is caused by a decrease in output per malignant LTCIC combined with an increase in the normal stem cell frequency. It is
concluded that bryostatin-1 selectively inhibits CML growth at the LTCIC level and should be explored as a purging modality in CML.
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Correspondence to: GJ OssenkoppeleIn view of these findings we investigated the effect of bryo-
statin-1 treatment on CFU–GM capacity in the presence of acces-
sory cells using unseparated mononuclear cells and in the absence
of accessory cells using purified CD34-positive cells. Cells were
obtained from 14 CML patients as well as from nine controls.
Moreover, CD34-positive cells derived from CML samples and
controls were analysed for stem cell frequency and ability using
the LTCIC assay at limiting dilution. Individual colonies derived
from these assays were analysed by fluorescent in situ hybridiza-
tion (FISH) for the presence of the bcr—abl gene to evaluate
selective inhibition of malignant colony growth.
MATERIALS AND METHODS
Patients and cell processing
Bone marrow was obtained from CML patients in first chronic
phase: unique patient number (UPN) 803, 906, 976, 1065, 1121,
1144, 1162, and from CML patients in blastic phase (BP): UPN
633 and 765. Samples UPN 971 and 1000 were obtained
via leukapheresis from CML patients in chronic phase. Samples
UPN 932, 1054, 1055, 1061, 1062, 1067, 1071, 1151 and
1152 were obtained from chronic phase CML patients via leuka-
pheresis after induction chemotherapy and granulocyte colony
stimulating factor (G-CSF, Filgrastim, Amgen, Breda, The
Netherlands) administration. Some of the total of 14 CML patients
were sampled more than once and each sample received its
own UPN number. Control bone marrows were obtained from
seven healthy volunteers and two control leukapheresis samples
were obtained from patients with breast cancer after peripheral
stem cell mobilization. All samples were obtained after informed
consent. Mononuclear cells were isolated from the samples by
Ficoll-Paque (Pharmacia, Upsala, Sweden) density gradient
centrifugation (d = 1.077 g cm–3). Remaining red cells were lysed
with ammonium chloride. CD34-positive cells were isolated using
the MiniMacs system (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the instructions of the manufacturer. After
two consecutive passages over two separation columns, purity was
always more than 90% as determined by FACS analysis.
Bryostatin-1 incubation
Bryostatin-1 was generously provided by Dr GR Petitt (Arizona
State University, Tempe, AZ, USA). Stock solutions of 10–3 and
10–4 M were made in dimethyl sulphoxide (DMSO) and stored at
–30°C until use. The cells were incubated at the desired bryostatin-
1 concentrations in Roswell Park Memorial Institute (RPMI), 10%
fetal calf serum (FCS) (Gibco, Grand Island, NY, USA) for the
desired pre-incubation period. After culturing the cells were
counted and scored with trypan blue exclusion for viability. The
final concentration of DMSO in cell culture media never exceeded
0.25%, a concentration which was determined to have no effect on
the CFU–GM capacity (data not shown).
Progenitor assays
CFU–GM
CD34-positive cells were cultured in semi-solid medium in the
presence of 5% human placenta conditioned medium (HPCM)
(Burgess et al, 1977) and 10% FCS (Gibco). Cultures were incu-
bated at 37°C in 5% carbon dioxide (CO2). The cells were plated at
four different concentrations: 500, 1000, 5000 and 10 000 CD34-
positive cells per ml CFU–GM medium, in triplicate to optimize
colony density for quantification and colony harvesting. Colonies
(> 40 cells) and clusters (8–40 cells) were counted at day 12 and
were plucked at random from different cultures with a vacuum
capillary system. The colony size was about 500 cells.
LTCIC (Sutherland et al, 1990)
Human bone marrow cultures were initiated with samples obtained
from healthy volunteers in long term bone marrow culture
(LTBMC) medium (Coulombel et al, 1983): alfa medium supple-
mented with 12.5% horse serum, 12.5% FCS, 10–4 M b-mercap-
toethanol, 10–6 M hydrocortisone sodium succinate, glutamine,
penicillin and streptomycin (all supplements from Gibco). After 2
weeks of culturing the adherent cells were harvested using trypsin
(Gibco), irradiated with 13 Gy (60Co) and plated in 96-well plates
(Costar, Cambridge, MA, USA) at 1.25 ´ 104 cells in 200 ml
LTBMC medium. After 2–7 days CD34-positive cells were plated
on top of the stromal cell layer and underwent a weekly half-
medium change. Cultures were incubated at 37°C in 5% CO2.
After 5 weeks the non-adherent and adherent cells (using trypsin)
were harvested and the CFU–GM capacity of cells was determined
as described earlier. The linearity between input of CD34-positive
cells and CFU–GM output of LTCICs was determined: long-term
cultures initiated with different concentrations of CD34-positive
cells (ranging from 1000 to 20 000 per well) were harvested and
plated in the CFU–GM assay, each at three different concentra-
tions. Experiments were done in triplicate. In addition for some
samples the frequency of the LTCIC cells (number of LTCICs per
CD34-positive cell) was determined with the limiting dilution
assay. CD34-positive cells were plated at concentrations of 50,
150, 500 and 1000 cells/well. After culturing for 5 weeks the cells
were harvested using trypsin and were subsequently plated in the
CFU–GM assay and scored after 2 weeks for positive/negative
results. The LTCIC frequencies were determined with Poisson
statistics (Sutherland et al, 1990). Combination of LTCIC-derived
CFU–GM output per CD34-positive cell with the frequency of
LTCIC per CD34-positive cell leads to the CFU–GM output/single
LTCIC: (CFU–GM output/CD34-positive cell)/(LTCIC/CD34-
positive cell) = (CFU–GM output/single LTCIC).
Molecular analysis
Interphase-FISH (I-FISH) was performed as described earlier
(Thijsen et al, 1997). Briefly, cells derived from a single colony
were put on a glass slide, fixed in 70% ethanol and dipped in a
0.1% gelatine (Sigma, St Louis, MO, USA) solution (Lakhotia 
et al, 1993) incubated with 0.1 mg ml–1 RNAse A (Boehringer
Mannheim, Mannheim, Germany) followed by 0.01% pepsin
(Sigma). Post-fixation the slides were dehydrated and denatured 
at 72°C in 70% formamide (Baker, Deventer, The Netherlands).
Cosmids bcr 51 and abl 18 (a kind gift from Dr G Grosveld and 
Dr A Hagemeijer, Erasmus University, Rotterdam, The
Netherlands) were labelled by nick-translation with digoxi-
genin11-dUTP (Boehringer Mannheim) and biotin-14-dATP
(Gibco), respectively (Arnoldus et al, 1990). An amount of 15 ng
of each probe was mixed with a 100-fold excess of Hu-cot-1 DNA
(Gibco) in 50% formamide, 2 ´ SSC and 10% dextran sulphate
(Sigma). This solution was denatured at 74°C for 4 min, cooled 
on ice and incubated at 37°C for 2 h and subsequently layered 
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onto the slides and sealed with rubber cement. After an overnight
hybridization at 37°C the cells were washed at 40°C with 55%
formamide in 2 ´ SSC, followed by 0.1 ´ SSC at 60°C. The biotin
labelled probe was detected with fluorescein avidin DN followed
by biotinylated anti-avidin and fluorescein avidin DN 
(all obtained from Vector Laboratories Inc., Burlingame, CA,
USA). The digoxigenin labelled probe was detected with anti-
digoxigenin–rhodamine (Boehringer Mannheim) followed by
Texas red-conjugated donkey anti-sheep (Jacksons Immuno-
research, West Grove, PA, USA). After dehydration slides were
embedded using Vectashield (Vector Laboratories Inc.) containing
0.1 mg ml–1 dapi (Sigma). Samples were scored with an Axioskop
50 (Carl Zeiss Jena GmBH, Jena, Germany) using a triple 
band pass filter (Omega Optical, Brattleboro, VT, USA). Nuclei
were scored positive for the bcr—abl gene when a green and a 
red spot were less than one spot diameter apart. A colony was
scored when at least ten nuclei could be evaluated. More than 90%
of the evaluable nuclei of a single colony should generate the 
same (positive or negative) result, otherwise a colony was con-
sidered not evaluable. On average 100 nuclei per colony were
evaluable.
RESULTS
Dose finding of bryostatin-1
The effect of bryostatin-1 treatment on the CFU–GM capacity of
cells from three CML patient bone marrow samples and three
control bone marrow samples was measured with the CFU–GM
assay. At time of sampling these patients were in advanced chronic
phase or in blastic phase as to make sure that the entire cell popu-
lation would be Ph-positive. The cells were pre-incubated for 24,
48, 72 and 96 h with 0, 10, 100, 250 and 500 nM bryostatin-1. The
readouts of the CFU–GM assays indicate a higher sensitivity of
CML-derived samples as compared to their normal counterparts.
These effects hold true especially for 250 and 500 nM and are
already achieved after 24 h of pre-incubation. More than a tenfold
increase in sensitivity of CML progenitors was observed towards
treatment with bryostatin as compared to the normal cells (data not
shown). This led us to analyse more samples in detail for the
effects of 24-hour pre-incubation with 250 nM bryostatin-1 on
normal and malignant haematopoiesis.
Effects of pre-incubation with 250 nM bryostatin-1 on
CFU–GM and LTCIC capacity
A total of 1000 CML-derived mononuclear cells generated a mean
output of 16 colonies/clusters in the CFU–GM assay (n = 9). For
the control samples this number was 10 (n = 6). A total of 100
CML-derived CD34-positive cells generated a mean output of 23
colonies/clusters in the CFU–GM assay (n = 8). For the CD34-
positive cells derived from the control samples this number was 20
(n = 5). The readouts of the CFU–GM assays show that upon treat-
ment with 250 nM bryostatin-1, in the presence of accessory cells,
on average 39% of the CFU–GM capacity remained as compared
to the CML cells pre-incubated without bryostatin-1. It should be
mentioned that four of these CML samples were analysed fresh
and five were analysed after cryopreservation and thawing. Both
groups showed a very similar bryostatin-1-induced reduction of
CFU–GM capacity. For the control samples, 56% of the clono-
genic capacity remained (Figure 1). The clonogenic capacity of
CD34-positive cells after treatment with bryostatin-1 was reduced
to 85% for the CML-derived samples, as compared to the CML
cells pre-incubated without bryostatin-1. For the control samples a
mean increase to 114% in clonogenic capacity could be observed
(Figure 1). Neither the unseparated mononuclear cells nor the puri-
fied CD34-positive cells showed significant differences between
the CML samples and control samples. However, the bryostatin-1-
induced reduction of CFU–GM capacity was significantly higher
(P < 0.05, Student’s t-test) in the presence of accessory cells, both
for the CML and control samples.
At the LTCIC level 100 CML-derived CD34-positive cells
generated a mean output of 43 colonies/clusters (n = 6). For
the CD34-positive cells derived from the control samples, this
number was 38 (n = 5) (Table 2). The readouts of the LTCIC
assays indicate a highly significant difference in effects of bryo-
statin-1-induced growth modulation on normal and malignant
haematopoiesis (P < 0.01, Student’s t-test). CD34-positive cells
derived from control samples were not affected significantly by
bryostatin-1 treatment, whereas CD34-positive cells derived from
CML samples showed a sixfold reduction in LTCIC-derived
CFU–GM output.
Molecular analysis of individual CFU–GM and LTCIC
colonies
In total, 799 colonies were analysed with FISH for the presence of the
bcr—abl gene. In a previous study, we analysed 160 colonies pairwise
both with reverse transcriptase polymerase chain reaction (RT–PCR)
(for the presence of the bcr–abl mRNA) and FISH (for the presence
of the bcr—abl gene) (Thijsen et al, 1997). We demonstrated a highly
significant correlation between both techniques.
At the CFU–GM level the molecular analysis of individual
CFU–GM colonies, generated by the unseparated mononuclear
cells, showed a mixture of bcr–abl-positive and -negative colonies
in three out of eight cases (Table 1). Upon bryostatin-1 treatment,
no significant change in the ratio between bcr–abl-positive/nega-
tive colonies was observed in cases UPN 1055 and 1152.
However, a statistically significant (P < 0.05, c2 test) relative loss
of bcr–abl-positive colonies in case UPN 1151 was detected while
in sample UPN 1162, a bcr–abl-negative colony could only be
detected after bryostatin-1 treatment. Concerning the CD34-posi-
tive cells, no shift was observed in case UPN 1055. A significant
increase in the number of bcr–abl-negative colonies could be
observed in case UPN 906 (P < 0.05, c2 test) while for UPN 971 a
bcr–abl-negative colony could only be detected after bryostatin-1
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Figure 1 Effects of bryostatin pre-incubation on CFU–GM capacity.
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treatment. At the LTCIC level (Table 2) six samples were
analysed. Bcr–abl-negative colonies were detected in a sample
derived from UPN 1121 after bryostatin-1 treatment whereas
without bryostatin treatment, no bcr–abl-negative colonies were
detected.
Effects of bryostatin-1 pre-incubation on LTCIC
frequency and CFU–GM output/LTCIC
To determine the effect of bryostatin-1 treatment on the stem cell
frequency and CFU–GM output/LTCIC, CD34-positive cells from
four CML samples and three control samples were analysed with
the LTCIC assay at limiting dilution. The four CML samples
showed a statistically significant (P < 0.05 Student’s t-test) 7.7-
fold reduction in LTCIC-derived CFU–GM output per CD34-posi-
tive cell (down to 13%) and an average stem cell frequency
reduction to 70% and was detected (Table 3); this indicates that
bryostatin-1 reduces the CFU–GM output per LTCIC 5.3-fold
(down to 19%). The three control samples showed no reduction in
the LTCIC-derived CFU–GM output per CD34-positive cell and
since an increase in the stem cell frequency was observed (up to
236%) this indicates only a moderate decrease to 66% in the
CFU–GM output per LTCIC.
The bryostatin-1 experiments have been performed after pre-
incubation for 24 h with or without bryostatin-1. However, when
comparing the CFU–GM output per LTCIC in the CML samples
pre-incubated without bryostatin-1 with fresh samples, a mean
Table 1 Effects of bryostatin-1: molecular analysis of individual CFU–GM coloniesa
Mononuclear cells CD34-positive cells
bcr–abl +/– coloniesa bcr–abl +/– coloniesa
UPN – bryo + bryo UPN – bryo + bryo
932c 17/0 16/0 932 24/0 50/0
1054 5/0 8/0 1054 6/0 9/0
1055c 13/13 (50)b 10/21 (68) 1055 4/5 (56) 5/5 (50)
1121 8/0 23/0 1121 23/0 20/0
1144 12/0 2/0 1144 16/0 14/0
1151c 10/10 (50) 2/20 (91)d 996 29/0 1/0
1152c 1/24 (96) 1/12 (92) 1000 23/0 27/0
1162c 20/0 (0) 17/1 (6) 971 18/0 (0) 35/1 (3)
906 22/6 (21) (19/20) (51)d
No col 96/47e 63/54 163/11 180/26
aNo. of bcr–abl (positive = +; negative = –) CFU–GM colonies. bNo. in parentheses indicate the percentages
cAnalysed after cryopreservation and thawing. dSignificantly different from the control (P < 0.01, c2 test). eNo. of
colonies (in total 640).
Table 2 Effects of bryostatin-1: clonogenic capacity and molecular analysis of individual LTCIC-derived coloniesa
LTCIC-derived CFU–GM
output/100 CD34 + cellsa bcr–abl +/– coloniesb
UPN – bryo + bryo – bryo + bryo
932 3.6 0.6 (17)d 5/0 8/0
1000 3.0 1.0 (33) 3/0 6/0
1054 98.0 12.7 (13) 18/0 16/0
1121 38.0 8.4 (22) 13/0 (0) 13/7 (35)e
1144 51.6 2.2 (4) 17/0 18/0
932c 63.6 8.2 (13) 19/0 16/0
75/0i 77/7
mean ± SEM 43 ± 15 5.5 ± 2.0 (17 ± 4)f
CM4g 1.3 2.3 (177)
CM5 0.6 0.17 (28)
CM6 56 54 (96)
LF1h 89 84 (94)
LF2 43.9 51.1 (116)
mean ± SEM 38 ± 17 38 ± 16 (102 ± 24)
aNo. of LTCIC-derived CFU–GM output/100 CD34-positive cells. bNo. of bcr–abl (Positive = +; negative = –)
LTCIC-derived CFU–GM colonies. cAnalysed after cryopreservation and thawing. dNo. in parentheses indicate the
percentages. eStatistically different from the untreated control (P < 0.05, c2 test). fStatistically different from the
control samples (P < 0.01, Students t-test). gCM, bone marrow samples obtained from three healthy volunteers.
hLF, leukapheresis samples obtained from patients with non-hematologic malignancy after stem cell mobilization.
iNo. of colonies (in total 159).1410 SFT Thijsen et al
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sixfold higher output (312 vs 50 colonies and clusters) was observed
(Table 3), accompanied by a decrease of stem cell frequency (1/416
vs 1/194). Since the only difference was the culturing period of 24 h,
three samples were analysed pairwise. In each case a 24-hour pre-
incubation led to a twofold increase in the CFU–GM output per
LTCIC and a decrease in the stem cell frequency.
DISCUSSION
The clonogenic capacity at the CFU–GM level showed an average
1.4-fold higher reduction after bryostatin-1 treatment in the CML
samples as compared to the control samples, both for the CD34-
positive cells and the unseparated mononuclear cells. These differ-
ences were not significant. Molecular analysis of individual
colonies showed a significant elimination of bcr–abl-positive
colonies in only two out of seven samples containing bcr–abl-
negative colonies and therefore supported the idea that the obser-
vation does reflect a true biological difference. These findings are
in line with the findings of Lilly et al (1990), who also demon-
strated a reduction in CML colony growth after pre-incubation
with bryostatin. Using CD34-positive cells, our results show an
only limited stimulation of CFU–GM outgrowth of control cells
after bryostatin pre-incubation, although in one bone marrow
sample we observed an almost twofold stimulation. These findings
are in contrast to others who observed a strong stimulation of
normal CFU–GM (Jones et al, 1990; Grant et al, 1991).
Remarkably, a significant (P < 0.05 Student’s t-test) twofold
higher reduction upon bryostatin-1 treatment was demonstrated in
samples using mononuclear cells as compared to the experiments
using CD34-positive cells, both with CML and control samples.
Unfortunately, the reduction at the CFU–GM level is the same for
CML and control samples and thus the presence of accessory cells
does not lead to selective loss of malignant cells. Since bryostatin-
1 induced release of TNF-a, from accessory cells such as mono-
cytes (Steube and Drexler, 1995; van der Hem et al) might play a
role in this phenomenon it can be argued that bcr–abl-positive
CFU–GMs are equally sensitive to TNF-a as control cells. A
similar effect has been described by the current authors for resis-
tance to TNF-a-mediated apoptosis induction in the bcr–abl-posi-
tive K562 cell line (Legdeur et al, 1996).
At the LTCIC level, we show evidence of a differential effect of
bryostatin-1 treatment on malignant vs normal haematopoiesis.
CML samples showed a sixfold reduction in LTCIC-derived
CFU–GM output per CD34-positive cell whereas bryostatin-1 treat-
ment did not affect the control samples. These results are highly
significant. Molecular analysis of individual colonies was unre-
warding since only one sample contained a mixture of bcr–abl-posi-
tive and -negative colonies. Interestingly these bcr–abl-negative
colonies were detected after bryostatin-1 treatment. These results
underline the importance of including assays for uncommitted prog-
enitors since purging effects of bryostatin-1 would have been largely
obscured when cells were analysed with the CFU–GM assay only.
LTCIC experiments were performed with CD34-positive cells
and, thus, bryostatin-1 may have a direct effect on the LTCICs, for
example by modulating the MAP kinase pathway (Sawyers et al,
1995). In this respect, the higher sensitivity of CML-derived
LTCICs as compared to the CML-derived CFU–GMs might be
explained by the possible absence of p210 in Ph-positive stem
cells (Bedi et al, 1993), leading to a possible increased vulnera-
bility for apoptosis of LTCICs compared to CFU–GMs (Bedi et al,
1994; McGahon et al, 1994). To study the effects of bryostatin-1
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.treatment in more detail, seven samples were analysed with the
LTCIC assay at limiting dilution. Analysis of four CML samples
showed that the observed effects are caused by a reduction in
CFU–GM output per LTCIC, while the reduction in stem cell
frequency is much less pronounced. In the three controls an overall
unchanged LTCIC-derived CFU–GM output per CD34-positive
cell was observed. The analysis at limiting dilution showed a
twofold increase in LTCIC frequency and a moderately reduced
CFU–GM output per LTCIC. Taken together, purging would thus
be a combined effect of a strongly reduced CFU–GM output per
malignant LTCIC and an increased normal stem cell frequency. In
future bryostatin could be explored as a possible purging agent in
the setting of autologous stem cell transplantation for those CML
patients not eligible for allogenic stem cell transplantation.
Moreover, dose finding studies for bryostatin have been performed
opening the way for in vivo purging strategies (Jayson et al, 1995;
Varterasian et al, 1998; Grant et al, 1998).
Remarkably, pre-incubation without bryostatin-1 resulted in
a higher CFU–GM output per LTCIC and a lower LTCIC
frequency as compared to samples not pre-incubated at all. This
indicates that culturing of cells on stromal feeder layer is very
different from culturing in suspension. Further studies should be
performed to investigate whether these observations might play a
role in the purging effect of bone marrow cultures (Barnett et al,
1994). In conclusion, bryostatin-1 selectively inhibits CML
growth, especially at the LTCIC level, and bryostatin-1 modula-
tion of haematopoiesis should be explored as a purging modality
in CML.
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